Marco Donia: Uncovering the Immunological Dynamics of MHC class II in Melanoma
Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital, shared a post on LinkedIn about a recent abstract by him and colleagues, presented at ESMO Immuno-Oncology Congress 2024:
“Uncovering the Immunological Dynamics of MHC class II in Melanoma.
Brilliant Mini-Oral presentation at ESMO Immuno24 by Mario Presti from CCIT-DK – National Center for Cancer Immune Therapy of Denmark.
Key findings:
- MHC class II positive melanoma: dedifferentiated phenotype
- CD4+ Immune Recognition almost exclusively through HLA-DR
- In vivo Loss of MHC Class II suggesting immunoediting
This research is relevant for several tumor types, as MHC II is expressed in melanoma, breast cancer, colorectal cancer, ovarian cancer, prostate cancer, classic Hodgkin lymphoma, glioma, and non–small cell lung cancer.
Big Thanks to:
- The patients who donated samples making this research possible;
- Fantastic co-author team with Irene Lobon, Marta Sánchez, Shawez Khan, and Samra Turajlic;
- Support by Lundbeck Foundation, Novo Nordisk Foundation, Danish Cancer Society, Independent Research Fund Denmark, The Francis Crick Institute, Herlev og Gentofte Hospital;
- Aurélien Marabelle for a thoughtful discussion of our data, the Scientific Committee of ESMO – European Society for Medical Oncology for selecting this abstract.
Stay tuned for more, full manuscript coming soon!”
“173MO – Immunological dynamics of HLA-II positive melanoma”
Authors: Mario Presti, Irene Lobon, Marta Sánchez, Shawez Khan, Samra Turajlic, Marco Donia.
More posts featuring Marco Donia.
Marco Donia is a Senior Consultant, Clinician-Scientist and Junior Research Group Leader (TIL group) at the Department of Oncology and Center for Cancer Immune Therapy, University of Copenhagen Herlev Hospital, Denmark. He serves as an Associate Professor in Clinical Oncology at the University of Copenhagen.
Donia is also a clinical oncologist treating patients with cancer immunotherapy. His research group is currently investigating new immune-regulatory circuits in PD-1/PD-L1 resistant tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023